Adolescent heroin use: A review

Pediatrics

Volumn 102, Issue 6, 1998, Pages 1461-1466

  Schwartz, Richard H ^a,b  

^a INOVA CHILDREN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Addiction; Chemical dependency; Drug abuse; Heroin

Indexed keywords

ANTITUSSIVE AGENT; CLONIDINE; CODEINE; DIAMORPHINE; LEVACETYLMETHADOL; METHADONE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 ACETATE; NALOXONE; NALTREXONE; OPIATE RECEPTOR; PAREGORIC; PERCOCET;

ADOLESCENT; ALCOHOLICS ANONYMOUS; CHILD BEHAVIOR; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG TOLERANCE; DRUG URINE LEVEL; HEALTH SURVEY; HEROIN DEPENDENCE; HIGH SCHOOL; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIFESTYLE; MANAGED CARE; METHADONE TREATMENT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 0031773488     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.102.6.1461     Document Type: Review

References (82)

1. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from: Monitoring the Future, 1975-1996. Ann Arbor, MI: University of Michigan Institute for Social Research; Rockville, MD: National Institute on Drug Abuse; 1995. Press release, December 18, 1997, University of Michigan, Ann Arbor
2. Office of the Attorney General, Crime, and Violence Prevention Center, California Department of Education, Department of Alcohol and Drug Programs, Department of Health Services. Sixth Biannual California Student Substance Use Survey, Grades 7, 9, and 11, 1995-1996. Sacramento, California. Table 3, p.10
3. Smith GM, Beecher HK. Subjective effects of heroin and morphine in normal subjects. Pain. 1962;136:47-52
4. Heroin. In: Cox TC, Jacobs MR, Leblanc AE, Marshman JA, eds. Drugs and Drug Abuse: A Reference Text. Toronto, Canada: Addiction Research Foundation; 1983:270-279
5. Martin WR. Pharmacology of the opioids. Pharmacol Rev. 1983;35: 283-323
6. DuPont RL. The Selfish Brain: Learning From Addiction. Washington, DC: American Psychiatric Press, Inc; 1997
7. Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Molecular Pharmacol. 1994; 45:330-334
8. US Department of Justice, Drug Enforcement Agency Intelligence Bulletin. Publication Nos. DEA-97004; 97006. Washington, DC: US Department of Justice, Drug Enforcement Agency; January 1997
9. Office of National Drug Control Policy. The National Drug Control Strategy: 1996. Washington, DC: Government Printing Office, Office of National Drug Control Policy Clearinghouse; 1997
10. Kandel D. Stages in adolescent involvement in drug use. Science. 1975; 190:912-914
11. Zinberg NE. On "chippers". Nova Law Review. 1987;11:999
12. Preble E, Casey JJ. Taking care of business: the heroin user's life on the street. Int J Addict. 1969;4:1-24
13. Drug Abuse Warning Network, National Institute on Drug Abuse, (1988-1991) and Substance Abuse and Mental Health Services Administration, (1992-1995). Washington, DC
14. Van de Wijngaart G. Heroin use in the Netherlands. Am J Drug Alcohol Abuse. 1988;1:125-136
15. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Parmacokinetics and pharmacodynamics of smoked heroin. J Anal Toxicol. 1994;18:317-330
16. Strang J, Griffiths P, Powis B, Gossop M. The first use of heroin: changes in route of administration over time. Br Med J. 1992;304:1222-1223
17. Griffiths P, Gossop M, Powis B, Strang J. Transitions in patterns of heroin chasers (chasing the dragon) and heroin injectors. Addiction. 1994;89:301-309
18. Bozarth MA, Wise RA. Anatomically distinct opiate receptor fields immediate reward and physical dependence. Science. 1984;224:516-517
19. Childers SR. Minireview: opioid receptor-coupled second messenger systems. Life Sci. 1991;48:1991-2003
20. Messinger E. Narcotic septal perforations due to drug addiction. JAMA. 1963;179:964-965
21. Joe GW, Simpson DD. Mortality rates among opioid addicts in a longitudinal study. Am J Public Health. 1987;77:347-348
22. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose. Addiction. 1995; 91:405-411
23. Gossop M, Griffiths, P, Powis B, Williamson S, Strang J. Frequency of non-fatal heroin overdose: survey of heroin users recruited in non-clinical settings. Br Med J. 1996;313:402
24. Zador D, Sanjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. Med J Aust. 1996;164: 204-207
25. Werling LL, Mc Mahon PN, Cox BM. Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA. 1989;86:6393-6397
26. Gold MS. Opiate addiction and the locus coeruleus. Psychiatr Clin North Am. 1993;16:61-73
27. Schwartz RH. Testing for drugs of abuse: controversies and techniques. Adolescent Medicine: State of the Art Reviews. 1993;4:353-370
28. Mule SJ, Casella GA. Rendering the "poppy-seed defense" defenseless: identification of 6-monoacetyl morphine in urine by gas chromatography/mass spectroscopy. Clin Chem. 1988; 34:1427-1430
29. Kranzler HR, Stone J, McLaughlin L. Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable. Drug Alcohol Depend. 1995:40:55-62
30. Staub C. Analytical procedures for determination of opiates in hair: a review. Forensic Sci Int. 1995;70:111-123
31. Klintz P, Mangin P. Evidence of gestational heroin or nicotine exposure by analysis of fetal hair. Forensic Sci Int. 1993;63:99-104
32. Ostrea EM Jr, Brady M, Gause S, et al. Drug screening of newborns by meconium analysis: a large-scale, prospective epidemiologic study. Pediatrics. 1992;89:107-113
33. Sporer KA, Firestone J, Isaacs SM. The prehospital treatment of heroin overdoses. Acad Emerg Med. 1995;2:448-452
34. Frand MI, Shim CS, Williams MH. Heroin-induced pulmonary edema: sequential studies of pulmonary function. Ann Intern Med. 1972;77: 29-35
35. Smith DA Leake L Loflin JR, Yealy DM. Is admission after intravenous heroin overdose necessary? Ann Emerg Med. 1992; 21:1638-1639
36. O'Connor PG, Samet JH, Stein MD. Management of hospitalized intravenous drug users: role of the internist. Am J Med. 1994;96:551-558
37. Gold MS, Pottash AC, Sweeney DR, Kleber HD. Opiate withdrawal using clonidine: a safe, effective, and rapid nonopiate treatment. JAMA. 1980;243;343-346
38. Clark HW, Longmuir N. Clonidine transdermal patches: a recovery oriented treatment of opiate withdrawal. California Society for the Treatment of Alcoholism and Other Drug Dependencies Newsletter. 1986;13:1-2
39. Vining E, Kosten TR, Kleber HD. Clinical utility of clonidine/naltrexone detoxification for opioid abusers. Br J Addict. 1988;83:567-575
40. O'Connor PG, Waugh ME, Schottenfeld RS, et al. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J Gen Intern Med. 1992;7:532-534
41. Stein MD. Clinical review: medical complications of intravenous drug use. J Gen Intern Med. 1990;5:249-257
42. Levine DP, Sobel JD. Infections in Intravenous Drug Abusers. New York, NY: Oxford University Press; 1991
43. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug abuser: 25 years later. Ann Intern Med. 1993;119:1017-1028
44. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med. 1993;153:2025-2030
45. Tennant F, Moll D. Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts. J Addict Dis. 1995;14:35-49
46. Huemer HP, Prodinger WM, Larcher C, et al. Correlation of hepatitis C virus antibodies with HIV seropositivity in intravenous drug users. Infection. 1990;18:122-123
47. Wartenberg AA. HIV disease in the intravenous drug user: role of the primary care physician. J Gen Intern Med. 1991;6(suppl):35-40
48. Dreyer NP, Fields BN. Heroin associated infective endocarditis. Ann Intern Med. 1973;78;699-702
49. French JF, Safford J. AIDS and intranasal heroin. Lancet. 1989;1:1082. Letter
50. Deykin EY, Buka SL, Zeenath TH. Depressive illness among chemically-dependent adolescents. Am J Psychiatry. 1992;149:1341-1347
51. Hovens JGFM, Cantwell DP, Kriiakos R. Psychiatric co-morbidity in hospitalized adolescent substance abusers. J Am Acad Child Adolesc Psychiatr. 1994;33:476-483
52. Peyrot M. Narcotics Anonymous: its history, structure, and approach. Int J Addict. 1985;20:1509-1522
53. Chappel JN. Effective use of AA and NA in treating patients. Psychiatr Ann. 1992;22:409-418
54. Sheeren AA. The relationship between relapse and involvement in Alcoholics Anonymous. J Stud Alcohol. 1988;49:104-106
55. Kaufman E, Reon J. Guidelines for the successful psychotherapy of substance abusers. Am J Drug Alcohol Abuse. 1988;14:199-209
56. Gonzales J, Brogden R. Naltrexone: review of its pharmacodynamic and pharmacokinetic properties and efficacy in the management of opioid dependence. Drugs. 1988;35:192-213
57. Rosenberg CM, Patch VD. Methadone use in adolescent heroin addicts. JAMA. 1972;220:991-993
58. Kosten TR. Current pharmacotherapies for opioid dependence. Psychopharmacol Bull. 1990;26:69-74
59. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA. 1992;276:253-258
60. Cooper JR. Ineffective use of psychoactive drugs: methadone treatment is no exception. JAMA. 1992;267:281-282
61. Caplehorn JR, Bell J, Kleinbaum DG, Gebski VJ. Methadone dose and heroin use during maintenance treatment. Addiction. 1993;88:119-124
62. Clark H. Opioids, chronic pain, and the law. J Pain Symptom Management. 1993;8:297-306
63. Wesson D, Ling W, Smith D. Prescription of opioids for treatment of pain in patients with addictive disease. J Pain Symptom Management. 1993;8:289-296
64. Savage SR. Management of acute and chronic pain and cancer pain in the addicted patient. In: Miller NS, ed. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1994
65. ASAM Patient Placement Criteria for Treatment of Substance-Related Disorders. 2nd ed. Washington, DC: American Society of Addiction Medicine; 1996
66. Winters K. Clinical consideration in the assessment of adolescent chemical dependency. J Adolesc Chem Dependency. 1990;1:31-52
67. Hoffmann NG, Miller NS. Treatment outcomes for abstinence-based programs. Psychiatr Ann. 1992;22:402-408
68. Smith DE, Schwartz RH, Gutgesell ME. Rehabilitation of chemically-dependent adolescents: a follow-up survey. Am J Dis Child. 1989;143: 413. Abstract
69. Anderson DF, Berlant JL. managed mental health and substance abuse services. In: PR Kongstvedt, ed. The Managed Care Handbook. 2nd ed. Gaithersburg, MD: Aspen Publishers, Inc
70. Edelman LB, Phalan A. Health maintenance organizations and the treatment of substance abuse. J Ambulatory Care Management. 1990;7: 181-188
71. Gaulden EC, Littlefield DC, Putoff OE. Menstrual abnormalities associated with heroin addiction. Am J Obstet Gynecol. 1964;90:155-160
72. Laura J. Miller. Detoxification of the addicted woman in pregnancy. In: Miller NS, ed. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1994
73. Hoegerman G, Schnoll S. Narcotic use in pregnancy. Clin Perinatol. 1991;18:51-76
74. Finnegan LP. Perinatal substance abuse. Semin Perinatol. 1991;15: 331-339
75. Gregg JEM, Davidson DC, Weindling AM. Inhaling heroin during pregnancy: effects on the baby. Br Med J. 1988;296:754
76. American Academy of Pediatrics, Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998;101:1079-1088
77. Besunder JB, Blumer JL. Neonatal drug syndromes. In: Koren G, ed. Maternal Fetal Toxicology. 2nd ed. New York, NY: Marcel Dekker, Inc; 1994:321-322
78. Madden JD, Chappel JN, Zuspan F, et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977;127:199-201
79. Alroomi LG, Davidson J, Evans TJ, Galea P, Howat R. Maternal narcotic abuse and the newborn. Arch Dis Child. 1988:63:81-83
80. Sherman JE, Zinser MC, Sideroff SI, Baker TB. Subjective dimensions of heroin urges: influence of heroin-related and affectively-related stimuli. Addict Behav. 1989;14:611-623
81. Brownell KD, Marlatt GA, Lichtenstein E, Wilson G. Understanding and preventing relapse. Am Psychol. 1986;41:765-782
82. Liddle H, Dakoff G, Diamond G. Adolescent substance abuse: multidimensional family therapy inaction. In: Kaufman E, Kaufmann P, eds. Family Therapy of Drug and Alcohol Abuse. 2nd ed. Boston, MA: Allyn and Bacon; 1992:120-171